Aman U. Buzdar, MD
Professor of Medicine
Department of Breast Medical Oncology
University of Texas MD Anderson Cancer Center
Joseph R. Singer, MD
Integrated Research Network
CME and CPE, 1 hour
This is the
second program in a two-part series based on live audioconference presentations.
By using newer diagnostic and therapeutic approaches, managed care has been able to have a profoundly positive effect on increased survival and improved outcomes for breast cancer patients. These interventions reduce disease progression, morbidity, and mortality, resulting in better clinical outcomes and in decreased overall utilization of healthcare resources. Clinical studies investigating third-generation aromatase inhibitors (AIs) alone, or adjuvant to tamoxifen, have shown significantly fewer rates of adverse events, disease recurrence, and contralateral breast tumors when they are used. This evidence was convincing enough to cause the National Comprehensive Cancer Network and the American Society of Clinical Oncology to change their clinical practice guidelines. Physicians are now recommended to consider using an AI as initial therapy in women with estrogen receptor-positive breast cancer, or to switch to an AI after 2 years of tamoxifen therapy rather than the traditionally recommended full 5 years. This audioconference will examine all medications within the third-generation AI class with the purpose of comparing them to tamoxifen and other currently available treatments. Managed care interests of improved clinical outcomes, cost-effectiveness, and determining the potential value of AIs will be addressed. Program Developer/Facilitator
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, and other physicians and pharmacists interested in the management of breast cancer.
Upon completion of this educational activity, the participant should be able to:
Identify best practices by delineating managed care strategies for optimal patient care and reduced resource utilization.
Explain the new ASCO and NCCN clinical guidelines and the rationale for their recommendations.
Delineate strategies for cost-saving approaches to identifying and treating hormone-receptor positive breast cancer patients.
Describe the findings of the major clinical trials (ATAC, BIG 1-98, MA-17, Italian Tamoxifen Arimidex trial and the Intergroup Exemestane Study) that compare aromatase inhibitor and tamoxifen treatments.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Buzdar discloses that he has received research fees, honoraria, and travel reimbursement from AstraZeneca.
Dr. Singer discloses that his employer, HealthCore Inc., is a health outcomes and medical research company that provides services to many pharmaceutical and biotech companies.
This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of breast cancer. Some uses of these agents may not have been approved by the FDA. Plase refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been assigned the Universal Program Number 077-999-06-004-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Commercial Support Statements
This program is supported by an educational grant from AstraZeneca.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Clicking "start the program" on the next screen will bring you to instructions to turn off pop-up blockers and allow you to begin the program presentation which will take approximately 60 minutes to complete.
The next screen will permit you to check for or download the Flash player required to run this program.
Upon completion of the program, click on the post-test button to register and access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.